Resources from the same session
25O - Phase I tolerability, persistence and pharmacodynamic (PD) profile of IV-administered next-generation adenoviral vectors supports clinical expansion in solid cancers
Presenter: Danny Khalil
Session: Abstract session 1
Resources:
Abstract
26O - Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors
Presenter: Giuseppe Curigliano
Session: Abstract session 1
Resources:
Abstract
Slides
Webcast
Invited discussant abstracts 25O and 26O
Presenter: Capucine Baldini
Session: Abstract session 1
Resources:
Slides
Webcast
43O - A dose-escalation study of TNO155 (TN) in combination with spartalizumab (SPA) or ribociclib (RIB) in adults with advanced solid tumors
Presenter: Omar Saavedra Santa Gadea
Session: Abstract session 1
Resources:
Abstract
Slides
Webcast
44O - Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
Presenter: Carlos Rojas
Session: Abstract session 1
Resources:
Abstract
Slides
Webcast
45O - First-in-human study of ABSK061: A selective fibroblast growth factor receptor (FGFR) 2/3 inhibitor for treating patients with advanced solid tumors
Presenter: Ji Zhu
Session: Abstract session 1
Resources:
Abstract
Slides
Webcast
27O - Interim results of a phase I/II trial of NT219 in combination with cetuximab in patients with advanced/metastatic squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Ari Rosenberg
Session: Abstract session 1
Resources:
Abstract
Slides
Webcast
Invited discussant abstracts 45O and 27O
Presenter: Irene Braña
Session: Abstract session 1
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Abstract session 1
Resources:
Webcast